The U.S. Supreme Court rejected a lawsuit claiming that Bayer's Roundup weedkiller caused cancer, a decision that will likely shield the company from thousands of similar cases pending in courts across the country.
The ruling stems from a case brought by a plaintiff who alleged exposure to glyphosate, Roundup's active ingredient, led to their cancer diagnosis. The Court's decision to reject the case means it will not hear arguments on the substance of those cancer claims. Instead, the justices left standing lower court rulings that favored Bayer.
This outcome has major implications for the litigation landscape. Thousands of plaintiffs have filed suits against Bayer alleging Roundup exposure caused various cancers, including non-Hodgkin lymphoma. Previously, some juries awarded substantial damages to individual plaintiffs, creating momentum for the legal campaign against the company. Those earlier verdicts put pressure on Bayer to negotiate settlements.
The Supreme Court's decision to reject the case effectively halts the momentum of the litigation. By declining to review the case, the Court avoided making a definitive ruling on whether glyphosate itself causes cancer. Instead, the decision rests on procedural grounds that favor Bayer's legal position.
The Environmental Protection Agency has maintained that glyphosate is safe for human use at approved exposure levels. The International Agency for Research on Cancer, part of the World Health Organization, classified glyphosate as "probably carcinogenic" in 2015, a designation that has fueled ongoing legal battles.
This Supreme Court decision does not resolve the scientific question of whether Roundup causes cancer in humans. Rather, it closes a particular legal avenue for plaintiffs seeking damages. Bayer faces continued scrutiny over Roundup's safety profile, but the company now has stronger legal footing against bulk litigation. Plaintiffs' attorneys will need to pursue individual